Column Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Column Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$49K	Buy	+401	New	+$51K	0.01%	327

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Column Capital Advisors's IBB Position: Q3 2023 in Review

Column Capital Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q3 2023: 401 shares worth $49K. The stake represents 0.01% of the portfolio and ranks #327 among its holdings.

833 funds tracked by Wall St. Rank hold IBB as of Q3 2023.

Column Capital Advisors held 401 shares of iShares Biotechnology ETF worth $49K as of Q3 2023.
iShares Biotechnology ETF was a new Column Capital Advisors position in Q3 2023.
iShares Biotechnology ETF made up 0.01% of Column Capital Advisors's portfolio in Q3 2023, its #327 holding.
833 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2023.

Based on Column Capital Advisors's 13F filing for Q3 2023, filed 3 Nov 2023.